Cancer Biomarker and Molecular Oncology
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Disease Biomarkers".
Deadline for manuscript submissions: 27 February 2026 | Viewed by 358
Special Issue Editor
Special Issue Information
Dear Colleagues,
Advances in cancer biomarker research and molecular oncology are driving precision medicine by enabling tailored therapies through tumor molecular profiling. These fields focus on identifying biological indicators and molecular pathways that inform diagnosis, prognosis, and treatment strategies, addressing challenges such as tumor heterogeneity and therapeutic resistance.
This Special Issue highlights cutting-edge research at the intersection of biomarker discovery, molecular mechanisms, and clinical translation. It explores topics such as liquid biopsies, multi-omics integration, and computational approaches to characterize tumor profiles and predict treatment responses. By synthesizing basic science and clinical insights, this Special Issue will foster innovations that enhance patient stratification and optimize targeted interventions.
We welcome submissions of original research and reviews that advance our understanding of cancer biomarkers and molecular pathways, particularly those with the potential to improve diagnostic accuracy and treatment efficacy. Together, these contributions will shape the future of personalized oncology, guiding the development of more precise and effective therapeutic strategies.
Dr. Jeane Silva
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer biomarkers
- molecular oncology
- precision medicine
- liquid biopsies
- therapeutic resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
